Abpro Holdings, Inc. (ABPO)
Healthcare · PNK
Price as at 30 Sept 2026, 15:57 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
Abpro Holdings, Inc. trades at $0.35, which is 30% below the $0.46 our fair value estimate puts on the business. On that measure alone it screens as undervalued, though a valuation model is an argument rather than a measurement, and the market is frequently right about why something is cheap.
Our moat model scores it 5 out of 100, which is little in the way of a moat. A moat is a structural reason competitors cannot take the profits away, and it matters more to a long holding period than any single quarter's numbers do.
It changes hands at 0.3 times earnings. Be careful reading that in isolation: for a cyclical business a low P/E arrives at the top of the cycle, when profits are peaking and about to fall, which is exactly when the shares look cheapest and are not.
About Abpro Holdings, Inc.
Abpro Holdings, Inc., a biotechnology company, focuses on the development of novel antibodies using discovery and engineering platforms for immuno-oncology, ophthalmology, and infectious disease in the United States. Its platforms include DiversImmune, an antibody discovery platform that generates a diverse collection of proprietary antibodies against clinically validated and novel targets; and MultiMab, an engineering platform that provides flexibility to combine antibody building blocks in different combinations and orientations to create fit-for-purpose novel full-length multispecific antibody constructs. The company's lead product candidates include ABP-102, a next-generation immuno-oncology TetraBi antibody targeting HER2 and CD3 developed for the treatment of HER2+ solid tumors, including breast and gastric cancers; and ABP-201, a TetraBi antibody format that simultaneously inhibits VEGF and ANG-2 for the treatment of vascular diseases of the eye, including diabetic macular edema and wet age-related macular degeneration. It also develops ABP-110, a TetraBi antibody targeting GPC3 and CD3 for the treatment of hepatocellular carcinoma; and ABP-150, a TetraBi antibody targeting claudin 18.2 and CD3 for the treatment of gastric cancers. The company has strategic partnerships with Celltrion Inc. and Abpro Bio International, Inc. Abpro Holdings, Inc. was incorporated in 2004 and is headquartered in Burlington, Massachusetts.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
ABPO passes 2 of our 30 screens today
Each screen prints the exact criteria it used, and the circumstances in which it is wrong.
ABPO peers
The largest companies in the same industry (Biotechnology), then in the same sector.
- CSLLY CSL Limited
- RVMD Revolution Medicines, Inc.
- CMXHF CSL Limited
- ALNY Alnylam Pharmaceuticals, Inc.
- RPRX Royalty Pharma plc
- INCY Incyte Corporation
- INSM Insmed Incorporated
- GNMSF Genmab A/S
Every healthcare company we cover is on the Healthcare hub.
Common questions
Is Abpro Holdings, Inc. (ABPO) undervalued?
Against our fair value estimate of $0.46, ABPO at $0.35 is 30% below fair value. That is one model's answer, not a recommendation. It is built from normalized earning power with growth capped deliberately low, which understates companies whose value is mostly future growth.
What is ABPO's P/E ratio?
ABPO trades at 0.3 times earnings. A low P/E is not automatically cheap: on a cyclical company it is usually a warning that earnings are at a peak.
Where does SteadyShares get its ABPO data?
Fundamentals for ABPO come from company filings and exchange data, as listed on PNK; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 30 Sept 2026, 15:57 UTC and is delayed. Our data quality score for this company is 63/100, which is the share of the inputs behind our scores that were actually available rather than assumed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for ABPO, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.